Business Context and Reporting Period
This Form 6-K filing covers the period ending September 30, 2004, for GlaxoSmithKline plc. The report is a notification of changes in directors' interests in the company's Ordinary Shares rather than a comprehensive financial statement.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on corporate governance and share ownership disclosures.
Material Changes
The primary material change reported is a transaction involving the GlaxoSmithKline Employee Trust (GSK Trust):
- Date: September 29, 2004
- Action: The GSK Trust transferred 225,000 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Notification: The Company was advised of this transaction on September 30, 2004.
Management Commentary and Risks
The filing notes that the GSK Trust is a discretionary trust where all employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Consequently, three directors—Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe—hold an interest in the shares held by the GSK Trust in the same capacity as other employees. No specific risks, contingencies, or unusual financial items are detailed in this text.
Investor Verification Checklist
- Verify the total number of shares held by the GSK Trust prior to and after the September 29, 2004 transfer.
- Confirm the specific shareholding details of Directors Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe outside of their interest in the Trust.
- Review the full terms of the SmithKline Beecham Employee Share Option Plan 1991 to understand vesting conditions for the 225,000 shares transferred.